Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1002/adhm.202001433 http://scihub22266oqcxt.onion/10.1002/adhm.202001433 33491915!7995163!33491915     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Adv+Healthc+Mater 2021 ; 10 (6): e2001433 Nephropedia Template TP {{tp|p=33491915|t=2021. Broad-Spectrum Antiviral Agents Based on Multivalent Inhibitors of Viral Infectivity |pdf=|usr=}}{{33491915}} gab.com Text Broad-Spectrum Antiviral Agents Based on Multivalent Inhibitors of Viral Infectivity JO: Adv Healthc Mater http://www.kidney.de/pget.php?&tw=1&pmid=33491915 #FOAvip The ongoing pandemic of the coronavirus disease (Covid-19), caused by the spread of the severe acute respiratory syndrome coronavirus 2 (SARS CoV-2), highlights the need for broad-spectrum antiviral drugs. In this Essay, it is argued that such agents already exist and are readily available while highlighting the challenges that remain to translate them into the clinic. Multivalent inhibitors of viral infectivity based on polymers or supramolecular agents and nanoparticles are shown to be broadly acting against diverse pathogens in vitro as well as in vivo. Furthermore, uniquely, such agents can be virucidal. Polymers and nanoparticles are stable, do not require cold chain of transportation and storage, and can be obtained on large scale. Specifically, for the treatment of respiratory viruses and pulmonary diseases, these agents can be administered via inhalation/nebulization, as is currently investigated in clinical trials as a treatment against SARS CoV-2/Covid-19. It is believed that with due optimization and clinical validation, multivalent inhibitors of viral infectivity can claim their rightful position as broad-spectrum antiviral agents. Twit Text FOAVip Broad-Spectrum Antiviral Agents Based on Multivalent Inhibitors of Viral Infectivity ????Adv Healthc Mater http://www.kidney.de/pget.php?&tw=1&pmid=33491915 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33491915 #FOAvip English Wikipedia <ref>{{Cite pmid|33491915}}</ref> Broad-Spectrum Antiviral Agents Based on Multivalent Inhibitors of Viral Infectivity #MMPMID33491915 Zelikin AN; Stellacci F Adv Healthc Mater 2021[Mar]; 10 (6): e2001433 PMID33491915show ga The ongoing pandemic of the coronavirus disease (Covid-19), caused by the spread of the severe acute respiratory syndrome coronavirus 2 (SARS CoV-2), highlights the need for broad-spectrum antiviral drugs. In this Essay, it is argued that such agents already exist and are readily available while highlighting the challenges that remain to translate them into the clinic. Multivalent inhibitors of viral infectivity based on polymers or supramolecular agents and nanoparticles are shown to be broadly acting against diverse pathogens in vitro as well as in vivo. Furthermore, uniquely, such agents can be virucidal. Polymers and nanoparticles are stable, do not require cold chain of transportation and storage, and can be obtained on large scale. Specifically, for the treatment of respiratory viruses and pulmonary diseases, these agents can be administered via inhalation/nebulization, as is currently investigated in clinical trials as a treatment against SARS CoV-2/Covid-19. It is believed that with due optimization and clinical validation, multivalent inhibitors of viral infectivity can claim their rightful position as broad-spectrum antiviral agents. |Antibodies, Neutralizing/therapeutic use[MESH] |Antiviral Agents/pharmacology/*therapeutic use[MESH] |COVID-19 Drug Treatment[MESH] |COVID-19/pathology/virology[MESH] |Humans[MESH] |Nanoparticles/chemistry/toxicity[MESH] |Polymers/chemistry/pharmacology[MESH] |SARS-CoV-2/drug effects/isolation & purification[MESH] |Virus Diseases/*drug therapy[MESH]Broad-Spectrum Antiviral Agents Based on Multivalent Inhibitors of Vir(epmc).pdf DeepDyve Pubget Overpricing